Kyverna Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Emeryville, CA
SEC filing record 1 source field available
Fiscal year end
31 December
Kyverna Therapeutics, Inc. has filed 182 SEC EDGAR filings since 05 Oct 2023

SEC filing history

Showing 126-150 of 182 matching filings.

Per page
25
Current page
6
SC 13D File 005-94441

SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

Filing date
03 May 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-K File 001-41947

10-K

Filing date
26 Mar 2024
Reporting date
31 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-41947

8-K

Filing date
26 Mar 2024
Reporting date
26 Mar 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-94441

SC 13G

Filing date
22 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-94441

SC 13G

Filing date
20 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
14 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
14 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
14 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
14 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
14 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-94441

SC 13G

Filing date
14 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filing date
13 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SEC STAFF LETTER

SEC STAFF LETTER filing

Filing date
13 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
12 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-41947

8-K

Filing date
12 Feb 2024
Reporting date
12 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-276952

S-8

Filing date
08 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B4 File 333-276523

424B4

Filing date
08 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CERT File 001-41947

CERT filing

Filing date
08 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
08 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
08 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-276523

EFFECT filing

Filing date
07 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
07 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
07 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
07 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3

Filing date
07 Feb 2024
Reporting date
07 Feb 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .